Diarrhea News and Research

Latest Diarrhea News and Research

Powerful painkiller on its way to the market: Experts worry about addiction woes

Drug makers are on their way to a pure, more powerful version of the nation’s second most-abused medicine, which has addiction experts worried that it could spur a new wave of abuse. The new pills contain the highly addictive painkiller hydrocodone, packing up to 10 times the amount of the drug as existing medications such as Vicodin.

28 Dec 2011

Celiac disease may increase risk of disordered eating, depression in women

Women with celiac disease -- an autoimmune disorder associated with a negative reaction to eating gluten -- are more likely than the general population to report symptoms of depression and disordered eating, even when they adhere to a gluten-free diet, according to researchers at Penn State, Syracuse University and Drexel University.

28 Dec 2011

FDA clears Meridian Bioscience's new Clostridium difficile assay

Meridian Bioscience, Inc., Cincinnati, Ohio today announced it has received FDA clearance for a new Clostridium difficile assay, ImmunoCard C. difficile GDH.

27 Dec 2011

ViroPharma to acquire Meritage

ViroPharma Incorporated today announced that it has entered into an exclusive option to acquire Meritage Pharma, Inc., a private company based in San Diego, CA focused on developing oral budesonide suspension (OBS) as a treatment for eosinophilic esophagitis (EoE), a chronic inflammatory disorder of the esophagus.

23 Dec 2011

Low-gluten beers can cause symptoms in patients with celiac disease

Beer tested in a new study, including some brands labeled "low-gluten," contains levels of hordein, the form of gluten present in barley, that could cause symptoms in patients with celiac disease (CD), the autoimmune condition treated with a life-long gluten-free diet, scientists are reporting.

22 Dec 2011

Government, humanitarian agencies respond to flooding in Philippines, warn of disease threat

"Philippine authorities are warning of the spread of diseases in cramped evacuation centers, days after flash floods hit the southern Philippines and claimed more than a thousand lives," ABC/Asia Pacific News reports, noting that flooding also has affected the country's northern provinces, displacing at least 50,000 people.

22 Dec 2011

Cholera education campaign launched in Somali capital

Health ministry officials on Friday launched a cholera education campaign in the Somali capital of Mogadishu, "which aims to educate at least one person in every household on preventing the disease and what to do when symptoms occur," Agence France-Presse reports.

21 Dec 2011

Takeda receives FDA approval for EDARBYCLOR to treat hypertension

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals North America, Inc., announced that the U.S. Food and Drug Administration (FDA) approved EDARBYCLOR (azilsartan medoxomil and chlorthalidone) for the treatment of hypertension to lower blood pressure in adults.

21 Dec 2011

Top-line results from Genzyme's teriflunomide and Rebif Phase III comparison trial on RMS

Genzyme, a Sanofi company, today reported top-line results from TENERE, a Phase III clinical trial comparing the effectiveness, safety and tolerability of once-daily oral teriflunomide to interferon beta-1a, an approved injectable therapy, in people with relapsing forms of multiple sclerosis.

20 Dec 2011

Eculizumab protects children from severe Shiga toxin-associated HUS

A physician and researcher at the Sainte Justine University Hospital Center (Sainte-Justine UHC), a University of Montreal affiliate, saved the life of a child and, by doing so, became the first to find a new use for a drug in the fight against deadly E. coli bacteria.

20 Dec 2011

Weight loss pill without major side effects coming soon

Scientists are on their way to develop a perfect diet pill. The drug, which switches off appetite using hormones that are created naturally in the stomach when it is full, could be the first to be effective in weight loss without side effects.

19 Dec 2011

Fluoride supplements not found to be safe or effective

According to the Cochrane Oral Health Group, fluoride supplements fail to reduce tooth decay in primary teeth, permanent teeth cavity-reduction is dubious and health risks are little studied.

19 Dec 2011

Soybean compounds can increase effectiveness of radiation treatment for lung cancer

A Wayne State University researcher has shown that compounds found in soybeans can make radiation treatment of lung cancer tumors more effective while helping to preserve normal tissue.

19 Dec 2011

Study aims to reduce mortality disparities by education

A study in the December issue of the American Sociological Review has brought new understanding as to why death rates for less educated middle aged adults are much higher than for their more educated peers despite increased awareness and treatments aimed at reducing health disparities.

16 Dec 2011

FDA approves modernized labeling for ViroPharma's Vancocin Capsules

ViroPharma Incorporated today announced the modernization of labeling for Vancocin (vancomycin hydrochloride, USP) Capsules made effective through the U.S. Food and Drug Administration's (FDA) approval of a supplemental new drug application.

15 Dec 2011

Salix submits Crofelemer NDA to FDA for treatment of HIV-associated diarrhea

Salix Pharmaceuticals, Ltd. today announced that the Company has submitted to the U.S. Food and Drug Administration (FDA) a New Drug Application (NDA) for Crofelemer for the proposed treatment of HIV-associated diarrhea.

14 Dec 2011

Celgene announces data from REVLIMID Phase III study on high-risk asymptomatic smoldering MM

Celgene International Sàrl, a subsidiary of Celgene Corporation, announced that updated data evaluating continuous treatment with REVLIMID (lenalidomide) in patients with high-risk asymptomatic smoldering multiple myeloma were presented at the 53rd Annual Meeting of the American Society of Hematology.

14 Dec 2011

CTI, Chroma announce final results from tosedostat phase II study on AML

Cell Therapeutics, Inc. and Chroma Therapeutics Ltd. announced that final results from the phase II OPAL study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia (AML) were presented by Jorge Cortes, M.D. of the University of Texas M.D. Anderson Cancer Center during the Acute Myeloid Leukemia - Therapy, excluding Transplantation: Clinical Studies session at the American Society of Hematology Annual Meeting.

14 Dec 2011

Vorinostat in addition to chemotherapy drugs improves remission rates in AML patients

Adding a drug that activates genes to frontline combination therapy for acute myeloid leukemia resulted in an 85 percent remission rate after initial treatment, researchers at The University of Texas MD Anderson Cancer Center reported at the 53rd Annual Meeting of the American Society of Hematology.

14 Dec 2011

'Twinning' team approach improves pediatric lymphoma outcomes

In an African county lacking any specialists in children's cancers, a team approach that "twins" Rwandan physicians with Boston-based pediatric oncologists has shown it can deliver expert, curative care to young patients stricken with lymphoma.

13 Dec 2011